Remetinostat

Cat. No.: HY-100365

CAS No.: 946150-57-8

Molecular Formula: $C_{16}H_{21}NO_6$

Molecular Weight: 323.34

Target: HDAC

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 150 mg/mL (463.91 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0927 mL	15.4636 mL	30.9272 mL
	5 mM	0.6185 mL	3.0927 mL	6.1854 mL
	10 mM	0.3093 mL	1.5464 mL	3.0927 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (7.73 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (7.73 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma[1].

IC_{50} & Target

HDAC[1].

REFERENCES

[1]. Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA